Promising Breakthrough in Parkinson's Disease Treatment: AC Immune Reports Positive Trial Results

In an encouraging development for Parkinson's disease research, AC Immune SA has announced significant findings from its Phase 2 trial of ACI-7104. The trial, named VacSYn, demonstrated that the investigational therapy was generally safe and well-tolerated among early-stage Parkinson's patients, with a remarkable 100% immunogenic response observed after three immunizations.

Key Findings from the VacSYn Trial

The Phase 2 trial has met all primary endpoints, focusing on safety, tolerability, and immunogenicity. Results included data from 34 patients, of whom 25 received the ACI-7104 treatment and nine were given a placebo. Strong antibody responses were noted, confirming the therapy's capability to generate targeted immune responses against the alpha-synuclein protein, a key player in the progression of Parkinson's disease.

Encouraging Signals and Future Plans

In addition to strong immune responses, the study observed a robust penetration of antibodies into the cerebrospinal fluid, further indicating the potential effectiveness of ACI-7104 in targeting neurodegenerative processes. While the initial phase did not evaluate clinical outcomes thoroughly, preliminary analyses suggested a correlation between immunogenicity and markers of disease activity, hinting at the therapy's broader implications.

Next Steps for AC Immune

Looking ahead, AC Immune is making plans to proceed with the next part of the trial, which will focus on providing evidence of clinical activity essential for advancing to a Phase 3 trial. The company is preparing to engage with regulatory bodies, including the FDA, in early 2027 to refine their development strategy for ACI-7104.

Martin Zügel, the Interim CEO of AC Immune, emphasized the importance of these results, stating that the favorable safety profile and significant immune responses lay a strong foundation for the therapy's future development. As the scientific community eagerly awaits further updates, this advancement represents a beacon of hope for patients battling Parkinson's disease.